Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MetaVia ( (MTVA) ) has provided an announcement.
On January 5, 2026, MetaVia reported positive, statistically significant data from the extended eight-week, non-titrated 48 mg multiple ascending dose cohort of its Phase 1 clinical trial of DA-1726 in obese but otherwise healthy adults, highlighting robust early weight loss, strong metabolic improvements and direct hepatic effects. Patients receiving DA-1726 achieved an average 9.1% (21.2 lb) weight loss, a 9.8 cm reduction in waist circumference, a 12.3 mg/dL drop in fasting glucose and a 23.7% reduction in liver stiffness by Day 54, with no treatment-related discontinuations and only mild to moderate gastrointestinal events, underscoring a favorable safety and tolerability profile and reinforcing DA-1726’s potential to emerge as a differentiated, best-in-class GLP-1/glucagon dual agonist in the increasingly competitive obesity and metabolic disease market.
The most recent analyst rating on (MTVA) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and worsening cash burn) and a negative P/E. Technicals are mixed/neutral with only mild signs of stabilization, while recent clinical and Nasdaq-compliance corporate updates provide a partial offset.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. Its lead programs include DA-1726, a novel oxyntomodulin analog dual agonist of GLP-1 and glucagon receptors in development for obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH), and vanoglipel (DA-1241), a GPR119 agonist targeting MASH and glucose control, both aimed at delivering superior weight loss, metabolic benefits and hepatic effects versus existing therapies.
Average Trading Volume: 189,215
Technical Sentiment Signal: Sell
Current Market Cap: $21.99M
See more insights into MTVA stock on TipRanks’ Stock Analysis page.